{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:24:19Z","timestamp":1792610659111,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115675","type":"journal-article","created":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T13:20:38Z","timestamp":1690118438000},"page":"115675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6\u2010Indolylpyridone\u20103\u2010Carbonitrile derivatives"],"prefix":"10.1016","volume":"259","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-5525","authenticated-orcid":false,"given":"Mohamed M.","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"El-Moselhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"El-Bastawissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaban R.M.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-Elamir F.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila A.","family":"Jaragh-Alhadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-6351","authenticated-orcid":false,"given":"Peter A.","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ejmech.2023.115675_bib1","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115675_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115675_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115675_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2014.12.003","article-title":"Co-targeting BRAF and cyclin dependent kinases 4\/6 for BRAF mutant cancers","volume":"149","author":"Yadav","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115675_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41419-019-1622-1","article-title":"Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin alpha5 in hepatocellular carcinoma","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115675_bib7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMoa0800668","article-title":"Detection of mutations in EGFR in circulating lung-cancer cells","volume":"359","author":"Maheswaran","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"28","key":"10.1016\/j.ejmech.2023.115675_bib8","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.ejmech.2023.115675_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR Axis revisited: implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115675_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99524-1","article-title":"CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer","volume":"11","author":"Gutiontov","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115675_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1758834010370698","article-title":"The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations","volume":"2","author":"Okamoto","year":"2010","journal-title":"Ther Adv Med Oncol"},{"issue":"21","key":"10.1016\/j.ejmech.2023.115675_bib14","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1158\/1078-0432.CCR-08-1455","article-title":"Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib","volume":"14","author":"Costa","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115675_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.6004\/jnccn.2013.0024","article-title":"Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers","volume":"11","author":"Yu","year":"2013","journal-title":"Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw"},{"issue":"15_suppl","key":"10.1016\/j.ejmech.2023.115675_bib16","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1200\/JCO.2021.39.15_suppl.9068","article-title":"Neratinib efficacy in a subgroup of patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: findings from the SUMMIT basket trial","volume":"39","author":"Goldman","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2023.115675_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jons.2016.07.008","article-title":"Antitumor activity of sorafenib on colorectal cancer","volume":"2","author":"Kacan","year":"2016","journal-title":"Journal of Oncological Sciences"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115675_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/onco.13689","article-title":"Activity of sorafenib plus capecitabine in previously treated metastatic colorectal cancer","volume":"26","author":"George","year":"2021","journal-title":"Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115675_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bcp.12651","article-title":"Vemurafenib\/dabrafenib and trametinib","volume":"80","author":"Rissmann","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115675_bib20","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1158\/1535-7163.MCT-10-0359","article-title":"BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro","volume":"9","author":"Dai","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115675_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22316","article-title":"Role of HGF\/c-Met in the treatment of colorectal cancer with liver metastasis","volume":"33","author":"Yao","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115675_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115675_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fendo.2019.00089","article-title":"When RON MET TAM in mesothelioma: all druggable for one, and one drug for all?","volume":"10","author":"Baird","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2023.115675_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.crchbi.2022.100040","article-title":"Covalent chemical probes for protein kinases","volume":"3","author":"Serafim","year":"2023","journal-title":"Current Research in Chemical Biology"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115675_bib25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5497\/wjp.v3.i4.162","article-title":"Pharmacophore approaches in protein kinase inhibitors design","volume":"3","author":"Starosyla","year":"2014","journal-title":"World J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115675_bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00044-017-1788-y","article-title":"Identification of novel MEK1 inhibitors by pharmacophore and docking based virtual screening","volume":"26","author":"Zou","year":"2017","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.115675_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.108114","article-title":"Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors","volume":"112","author":"Shaikh","year":"2022","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2023.115675_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105161","article-title":"Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents","volume":"114","author":"Singh","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115675_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4155\/fmc-2019-0062","article-title":"Development and strategies of CDK4\/6 inhibitors","volume":"12","author":"Chen","year":"2019","journal-title":"Future Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncomms1081","article-title":"Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules","volume":"1","author":"Galloway","year":"2010","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115675_bib31","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/jhet.5570440641","article-title":"An efficient and facile procedure for the synthesis of 4,6-diaryl-2(1H)-pyridones under solvent-free conditions","volume":"44","author":"Rong","year":"2007","journal-title":"J. Heterocycl. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115675_bib32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.tetlet.2013.12.081","article-title":"Synthesis of 4-aryl-6-indolylpyridine-3-carbonitriles and evaluation of their antiproliferative activity","volume":"55","author":"El-Sayed","year":"2014","journal-title":"Tetrahedron Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115675_bib33","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1021\/jo01066a029","article-title":"Synthesis of 3-hydroxypyridines. II. Preparation of unsaturated cyano esters and their reaction with diazomethane1-3","volume":"26","author":"Popp","year":"1961","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115675_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejmech.2014.01.049","article-title":"Synthesis and structure\u2013activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel","volume":"75","author":"Rodrigues","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/acs.jmedchem.2c01818","article-title":"Mechanistic insight of synthesized 1,4-dihydropyridines as an antidiabetic sword against reactive oxygen species","volume":"66","author":"Sidhom","year":"2023","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115675_bib36","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Ikediobi","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115675_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/1878-0261.12849","article-title":"Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products","volume":"15","author":"Krushkal","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2023.115675_bib38","series-title":"Cancer Cell Culture: Methods and Protocols","first-page":"237","article-title":"Cell sensitivity assays: the MTT assay","author":"van Meerloo","year":"2011"},{"issue":"11","key":"10.1016\/j.ejmech.2023.115675_bib39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2023.115675_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102944","article-title":"Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR\/HER2 inhibitors and apoptosis inducers","volume":"88","author":"Elmetwally","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115675_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000022","article-title":"Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents","volume":"353","author":"Yousefian","year":"2020","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115675_bib43","first-page":"1136","article-title":"RET in breast cancer: pathogenic implications and mechanisms of drug resistance","volume":"2","author":"Lo Nigro","year":"2019","journal-title":"Cancer Drug Resist"},{"issue":"19","key":"10.1016\/j.ejmech.2023.115675_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197108","article-title":"RET receptor tyrosine kinase: role in neurodegeneration, obesity, and cancer","volume":"21","author":"Mahato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115675_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020354","article-title":"Cell line models for acquired resistance to first-line osimertinib in lung cancers-applications and limitations","volume":"10","author":"Ohara","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: a double role in lung cancer cell survival?","volume":"4","author":"Suda","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2023.115675_bib47","first-page":"11","article-title":"c-Met mutational analysis in the sema and juxtamembrane domains in small-cell-lung-cancer","volume":"1","author":"de Aguirre","year":"2006","journal-title":"Transl. Oncogenomics"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115675_bib49","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115675_bib50","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/1759-7714.12765","article-title":"Comparison and discussion of the treatment guidelines for small cell lung cancer","volume":"9","author":"Zhao","year":"2018","journal-title":"Thorac Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115675_bib51","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000245937","article-title":"Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death","volume":"84","author":"Kim","year":"2009","journal-title":"Pharmacology"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115675_bib52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s12031-014-0244-4","article-title":"Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death","volume":"54","author":"Scuderi","year":"2014","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/cdd.2017.174","article-title":"Mechanisms of transcriptional regulation by p53","volume":"25","author":"Sullivan","year":"2018","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115675_bib54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/17474086.2013.827415","article-title":"The Bcl-2\/Bax and Ras\/Raf\/MEK\/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches","volume":"6","author":"Vitagliano","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115675_bib55","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.celrep.2020.01.074","article-title":"Pulsatile MAPK signaling modulates p53 activity to control cell fate decisions at the G2 checkpoint for DNA damage","volume":"30","author":"De","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2023.115675_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.redox.2018.05.017","article-title":"PARP1 promoter links cell cycle progression with adaptation to oxidative environment","volume":"18","author":"Pietrzak","year":"2018","journal-title":"Redox Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115675_bib57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neo.2020.12.006","article-title":"Tumor necrosis factor in lung cancer: complex roles in biology and resistance to treatment","volume":"23","author":"Gong","year":"2021","journal-title":"Neoplasia"},{"issue":"29","key":"10.1016\/j.ejmech.2023.115675_bib58","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1038\/onc.2013.356","article-title":"TNF-alpha\/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells","volume":"33","author":"Oshima","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2023.115675_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fcell.2019.00107","article-title":"In vitro cell migration, invasion, and adhesion assays: from cell imaging to data analysis","volume":"7","author":"Pijuan","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115675_bib60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/(SICI)1096-9896(199612)180:4<389::AID-PATH685>3.0.CO;2-K","article-title":"Immunoreactivity for hepatocyte growth factor\/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas","volume":"180","author":"Harvey","year":"1996","journal-title":"J. Pathol."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115675_bib61","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6601718","article-title":"The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients","volume":"90","author":"Masuya","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115675_bib62","article-title":"In vitro cell migration and invasion assays","volume":"88","author":"Justus","year":"2014","journal-title":"J. Vis. Exp."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115675_bib63","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"W1","key":"10.1016\/j.ejmech.2023.115675_bib65","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115675_bib66","series-title":"Solutions, the PreADME Approach: Web-Based Program for Rapid Prediction of Physico-Chemical, Drug Absorption and Drug-like Properties","first-page":"418","author":"Lee","year":"2003"},{"key":"10.1016\/j.ejmech.2023.115675_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104877","article-title":"Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: in vitro, in vivo, and in silico integrated approaches","volume":"111","author":"Boraei","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115675_bib68","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1039\/C1GC15925A","article-title":"Critical assessment of the efficiency of chitosan biohydrogel beads as recyclable and heterogeneous organocatalyst for C\u2013C bond formation","volume":"14","author":"K\u00fchbeck","year":"2012","journal-title":"Green Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115675_bib69","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1021\/acs.jmedchem.0c01570","article-title":"Development of novel mitochondrial pyruvate carrier inhibitors to treat hair loss","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115675_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/ejoc.202200112","article-title":"Enantioselective cyclopropanation of 2-Cyano-3-arylacrylates using carbohydrate-based crown ethers","volume":"2022","author":"Orb\u00e1n","year":"2022","journal-title":"Eur. J. Org Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115675_bib71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3184\/030823409X12616597939085","article-title":"Green and efficient Knoevenagel condensation catalysed by a DBU based ionic liquid in water","volume":"34","author":"Ying","year":"2010","journal-title":"J. Chem. Res."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115675_bib72","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1055\/s-0039-1690621","article-title":"Hypervalent iodine(III)-Catalyzed epoxidation of \u03b2-cyanostyrenes","volume":"51","author":"Mangaonkar","year":"2019","journal-title":"Synthesis"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:57:38Z","timestamp":1759330658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423006414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":71,"alternative-id":["S0223523423006414"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115675","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6\u2010Indolylpyridone\u20103\u2010Carbonitrile derivatives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115675"}}